Compare Gilead Sciences, Inc. (GILD) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Marvell Technology Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Marvell Technology Inc trades at $275.28 (market cap $246.84B). The key difference: Marvell Technology Inc is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Marvell Technology Inc for 42 Days on average.
| GILD | MRVL | |
|---|---|---|
Market Cap | $182.40B | $246.84B |
Volume | 4,469,821 | 29,003,830 |
Sector | Health | Technology |
52-Week High | $155.80 | $316.43 |
52-Week Low | $116.74 | $73.73 |
Typical Hold Time | 111 Days | 42 Days |
Enterprise Value | $205.46B | $248.19B |
Dividend Yield | 2.23% | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day, but maintains strong analyst support with 84% buy ratings and a $327.86 consensus price target. The stock shows bullish technical signals with support at $267 and resistance at $282, while recent earnings beats and projected revenue growth to $9.5B in 2026 highlight fundamental momentum. Management's raised 2028 revenue guidance to $18B and major hyperscaler deals underscore the company's positioning in AI infrastructure.
Outlook remains positive driven by AI chip demand and custom silicon growth, though high valuations (P/E 90.95) and margin pressures present risks. The stock offers significant upside to analyst targets but requires monitoring of execution against aggressive growth forecasts and competitive dynamics in the semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
